Loading…
Nomida.biz was cited for illegally selling unapproved and misbranded semaglutide and tirzepatide drugs online to U.S. consumers in violation of the Federal Food, Drug, and Cosmetic Act sections 301(a), 301(d), 301(k), 503(b), and 505(a). The company failed to obtain FDA approval before introducing these new drugs into interstate commerce, and the products lacked required regulatory oversight and safety assurances. The FDA warned that unapproved drugs sold through circumvented regulatory channels pose inherent risks of contamination, counterfeiting, inconsistent active ingredient amounts, or ingredient substitution, and requested immediate cessation of all unapproved and misbranded drug sales.